FASENRA® is the commercial brand name of Benralizumab Injection, a humanized monoclonal antibody targeting interleukin-5 receptor alpha developed by AstraZeneca. It binds to IL-5 receptor α expressed on eosinophils to induce direct depletion of eosinophils, thereby alleviating eosinophil-mediated airway inflammation.
Main Indications
Add-on maintenance treatment of severe eosinophilic asthma in adult patients.
Clinical Research
Global multicenter phase III trials demonstrated that benralizumab effectively reduces peripheral and airway eosinophils, cuts the annual rate of asthma exacerbations and supports the reduction of maintenance oral corticosteroids;
Registration trials among Chinese participants confirmed stable therapeutic efficacy and comparable tolerability data with global research cohorts;
Long-term observational studies verified persistent asthma symptom control and a manageable safety profile during repeated subcutaneous injection.
Common Side Effects
Severe but important risks: Severe hypersensitivity reactions including anaphylaxis;
Common mild adverse reactions: Headache, pharyngitis, injection site reactions, pyrexia and back pain.
Approval Status in China
Original drug FASENRA® (Benralizumab Injection) was officially approved for marketing in China in 2020. It is currently a prescription biologic drug indicated for severe eosinophilic asthma.
Buy FASENRA (Benralizumab Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
